Erratum: Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer (Clinical Cancer Research (2019) 12(5199–5206)Doi:10.1158/1078-0432.CCR-06-0429)

This article (1) has been retracted at the request of the editors. Following an institutional review by Ohio State University, the primary affiliation for several of the authors, it was determined that data in Fig. 4A was falsified. As a result of these findings, the institution recommended retraction and, upon internal review, the editors agreed with this recommendation. A copy of this Retraction Notice was sent to the last known e-mail addresses for all authors. Two authors (Samuel K. Kulp and Ching-Shih Chen) agreed to the retraction, and three authors (Chang-Shi Chen, Da-Sheng Wang, and Ching-Yu Chen) did not respond.